KNSA Stock Summary and Trading Ideas (Kiniksa Pharmaceuticals Ltd. - Class A | NASDAQ:KNSA)

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Kiniksa Pharmaceuticals Ltd. - Class A trades on the NASDAQ stock market under the symbol KNSA.

As of March 14, 2025, KNSA stock price climbed to $22.61 with 463,179 million shares trading.

KNSA has a beta of 0.77, meaning it tends to be less sensitive to market movements. KNSA has a correlation of 0.06 to the broad based SPY ETF.

KNSA has a market cap of $1.64 billion. This is considered a Small Cap stock.

Last quarter Kiniksa Pharmaceuticals Ltd. - Class A reported $123 million in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-844,000 and missed earnings estimates by -$.25.

In the last 3 years, KNSA traded as high as $28.15 and as low as $7.36.

The top ETF exchange traded funds that KNSA belongs to (by Net Assets): IWM, VTI, VB, VBK, IWO.

KNSA has outperformed the market in the last year with a price return of +10.5% while the SPY ETF gained +10.4%. KNSA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +11.9% and +15.2%, respectively, while the SPY returned -6.5% and -3.8%, respectively.

KNSA support price is $21.51 and resistance is $22.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KNSA shares will trade within this expected range on the day.